News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Week in Review: Hutchison Medipharma Partners Cancer Drug With Eli Lilly and Company (LLY)


10/14/2013 7:49:29 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

October 12, 2013 -- Hutchison MediPharma, a Chi-Med subsidiary, will partner its cancer drug fruquintinib with Lilly in a deal potentially worth $86.5 million; ASLAN Pharma of Singapore completed a Series B financing that brought in $22 million; Eddingpharm acquired China rights to Immutep’s ImmunFact IMP321, an immuno-treatment for breast cancer; Shenzhen Chipscreen Biosciences out-licensed Taiwanese rights for a cancer drug candidate to a Taiwanese startup; Sihuan Pharma received CFDA approval to begin clinical trials of pirotinib, an innovative cancer drug; a vaccine for Japanese encephalitis developed by China National Biotec was prequalified by the World Health Organization; Hutchison MediPharma will receive a $6 million milestone payment from Janssen Pharma in an inflammation drug partnership; two scientists formerly employed by Eli Lilly were indicted for passing proprietary information to an employee of Jiangsu Hengrui Medicine; and China police have arrested another suspect in the GlaxoSmithKline bribery case. More details….

Stock Symbol: (AIM: HCM) (NYSE: LLY) (HK: 0460) (NYSE: GSK)

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES